Meditor Group Ltd is required to file a 13D/G report to the SEC when the ownership of a company's total stock issue exceeds 5%.
| Shares | Percentage | ||||
|---|---|---|---|---|---|
| EXELIXIS, INC. | 15,001,073 | 5.0% | April 09, 2019 | EDGAR | |
| VIVUS INC | 5,002,896 | 5.0% | December 19, 2012 | EDGAR | |
| VIVUS INC | 6,177,500 | 6.3% | March 21, 2012 | EDGAR | |
| VION PHARMACEUTICALS INC | 5,736,200 | 7.6% | February 15, 2008 | EDGAR | |
| CYPRESS BIOSCIENCE INC | 1,864,645 | 5.0% | September 26, 2007 | EDGAR | |
| ONYX PHARMACEUTICALS INC | 2,627,800 | 4.8% | September 12, 2007 | EDGAR | |
| ACUSPHERE INC | 1,839,421 | 4.0% | July 26, 2007 | EDGAR | |
| NOVACEA INC | 800,000 | 3.4% | June 11, 2007 | EDGAR | |
| ATHEROGENICS INC | 1,361,800 | 3.5% | May 02, 2007 | EDGAR |
- Meditor Group Ltd holdings (13F-HR)
- Meditor Group Ltd significant holdings (13D/G)
- Meditor Group Ltd ownership history
- Meditor Group Ltd portfolio value
- Meditor Group Ltd filings
- Similar filers BETA
Compare quarterly holdings
Export Meditor Group Ltd's holdings